104 related articles for article (PubMed ID: 21077681)
1. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
[TBL] [Abstract][Full Text] [Related]
4. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Milo LJ; Lai JH; Wu W; Liu Y; Maw H; Li Y; Jin Z; Shu Y; Poplawski SE; Wu Y; Sanford DG; Sudmeier JL; Bachovchin WW
J Med Chem; 2011 Jul; 54(13):4365-77. PubMed ID: 21634429
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
[TBL] [Abstract][Full Text] [Related]
6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Dorsey BD; Iqbal M; Chatterjee S; Menta E; Bernardini R; Bernareggi A; Cassarà PG; D'Arasmo G; Ferretti E; De Munari S; Oliva A; Pezzoni G; Allievi C; Strepponi I; Ruggeri B; Ator MA; Williams M; Mallamo JP
J Med Chem; 2008 Feb; 51(4):1068-72. PubMed ID: 18247547
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
10. Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
Purandare AV; Wan H; Laing N; Benbatoul K; Vaccaro W; Poss MA
Bioorg Med Chem Lett; 2004 Sep; 14(18):4701-4. PubMed ID: 15324891
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Abe H; Momose I; Takahashi Y; Ikeda D; Akamatsu Y
Bioorg Med Chem Lett; 2010 Oct; 20(19):5839-42. PubMed ID: 20727746
[TBL] [Abstract][Full Text] [Related]
14. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
Lu C; Gallegos R; Li P; Xia CQ; Pusalkar S; Uttamsingh V; Nix D; Miwa GT; Gan LS
Drug Metab Dispos; 2006 Apr; 34(4):702-8. PubMed ID: 16443666
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
18. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
Marx C; Yau C; Banwait S; Zhou Y; Scott GK; Hann B; Park JW; Benz CC
Mol Pharmacol; 2007 Jun; 71(6):1525-34. PubMed ID: 17392524
[TBL] [Abstract][Full Text] [Related]
19. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
